Literature DB >> 33539397

Survival in untreated hepatocellular carcinoma: A national cohort study.

Young Ae Kim1, Danbee Kang2,3, Hyeyoung Moon2, Donghyun Sinn4, Minwoong Kang3,5, Sang Myung Woo6, Yoon Jung Chang1, Boram Park7, Sun-Young Kong8, Eliseo Guallar9, Soo-Yong Shin5, Geunyeon Gwak4, Joung Hwan Back10, Eun Sook Lee11, Juhee Cho2,3,5,9.   

Abstract

This study aimed to analyze the proportion, characteristics and prognosis of untreated hepatocellular carcinoma (HCC) patients in a large representative nationwide study. A cohort study was conducted using the National Health Insurance Service (NHIS) database in Korea. A total of 63,668 newly-diagnosed HCC patients between January 2008 and December 2013 were analyzed. Patients were categorized into treatment group and no treatment group using claim codes after HCC diagnosis. The proportion of untreated HCC patients was 27.6%, decreasing from 33.4% in 2008 to 24.8% in 2013. Compared to treated patients, untreated patients were more likely to be older (P < 0.001), female (P < 0.01), to have a distant SEER stage (P < 0.001), severe liver disease (P < 0.001), and lower income (P < 0.001). The fully-adjusted hazard ratio for all-cause mortality comparing untreated to treated patients was 3.11 (95% CI, 3.04-3.18). The risk of mortality was higher for untreated patients in all pre-defined subgroups, including those with distant SEER stage and those with severe liver disease. About one fourth of newly diagnosed HCC patients did not receive any HCC-specific treatment. Untreated patients showed higher risk of mortality compared to treated patients in all subgroups. Further studies are needed to identify obstacles for HCC treatment and to improve treatment rates.

Entities:  

Mesh:

Year:  2021        PMID: 33539397      PMCID: PMC7861368          DOI: 10.1371/journal.pone.0246143

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  33 in total

Review 1.  2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-08-10

Review 2.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2018-04-05       Impact factor: 25.083

Review 3.  Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability.

Authors:  Katherine A McGlynn; Jessica L Petrick; W Thomas London
Journal:  Clin Liver Dis       Date:  2015-02-26       Impact factor: 6.126

4.  Prognosis of untreated hepatocellular carcinoma.

Authors:  Edoardo G Giannini; Fabio Farinati; Francesca Ciccarese; Anna Pecorelli; Gian Lodovico Rapaccini; Mariella Di Marco; Luisa Benvegnù; Eugenio Caturelli; Marco Zoli; Franco Borzio; Maria Chiaramonte; Franco Trevisani
Journal:  Hepatology       Date:  2014-11-26       Impact factor: 17.425

5.  Treatment of hepatocellular carcinoma with Child-Pugh C cirrhosis.

Authors:  Kazuhiro Nouso; Norihiro Kokudo; Masatoshi Tanaka; Ryoko Kuromatsu; Hiroki Nishikawa; Hidenori Toyoda; Naoki Oishi; Kenji Kuwaki; Masashi Kusanaga; Takuki Sakaguchi; Zenichi Morise; Satoshi Kitai; Masatoshi Kudo
Journal:  Oncology       Date:  2014-11-22       Impact factor: 2.935

6.  A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function.

Authors:  Hyun Yang; Hyun Young Woo; Soon Kyu Lee; Ji Won Han; Bohyun Jang; Hee Chul Nam; Hae Lim Lee; Sung Won Lee; Do Seon Song; Myeong Jun Song; Jung Suk Oh; Ho Jong Chun; Jeong Won Jang; Angelo Lozada; Si Hyun Bae; Jong Young Choi; Seung Kew Yoon
Journal:  Clin Mol Hepatol       Date:  2017-05-10

Review 7.  Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data.

Authors:  Jee Ae Kim; Seokjun Yoon; Log Young Kim; Dong Sook Kim
Journal:  J Korean Med Sci       Date:  2017-05       Impact factor: 2.153

Review 8.  Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?

Authors:  Ibrahim A Hanouneh; Naim Alkhouri; Amit G Singal
Journal:  Clin Mol Hepatol       Date:  2019-03-04

Review 9.  A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016.

Authors:  Su Jong Yu
Journal:  Clin Mol Hepatol       Date:  2016-03-28

10.  Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients.

Authors:  Dong Hyun Sinn; Gyu-Seong Choi; Hee Chul Park; Jong Man Kim; Honsoul Kim; Kyoung Doo Song; Tae Wook Kang; Min Woo Lee; Hyunchul Rhim; Dongho Hyun; Sung Ki Cho; Sung Wook Shin; Woo Kyoung Jeong; Seong Hyun Kim; Jeong Il Yu; Sang Yun Ha; Su Jin Lee; Ho Yeong Lim; Kyunga Kim; Joong Hyun Ahn; Wonseok Kang; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Jae-Won Joh; Hyo Keun Lim; Seung Woon Paik
Journal:  PLoS One       Date:  2019-01-14       Impact factor: 3.240

View more
  1 in total

1.  Proton Beam Therapy for Multifocal Hepatocellular Carcinoma (HCC) Showing Complete Response in Pathological Anatomy After Liver Transplantation.

Authors:  Yinuo Li; Shosei Shimizu; Masashi Mizumoto; Takashi Iizumi; Haruko Numajiri; Hirokazu Makishima; Gong Li; Hideyuki Sakurai
Journal:  Cureus       Date:  2022-06-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.